Rotigotine and parkinsonism-hyperpyrexia syndrome

Area of Science:

• Neurology
• Pharmacology

Background:

• Parkinsonism-hyperpyrexia syndrome (PHS) is a critical complication of Parkinson's disease (PD), frequently triggered by alterations in antiparkinsonian medications.
• Rotigotine, a continuous-delivery transdermal dopamine agonist, offers an alternative administration route, especially when oral intake is challenging.

Purpose of the Study:

• To investigate the association between rotigotine use and the development of PHS in hospitalized PD patients.
• To identify clinical factors and precipitating events associated with PHS.

Main Methods:

• Retrospective review of 147 emergency hospitalizations for PD.
• Comparison of clinical characteristics, medication use, and precipitating factors between PHS and non-PHS groups.
• Multivariable logistic regression analysis to assess predictors of PHS, including rotigotine administration.

Main Results:

• The PHS group exhibited shorter disease duration and lower medication doses compared to the non-PHS group.
• Poor medication compliance was the primary precipitating factor for PHS.
• Rotigotine administration showed a trend towards suppressing PHS development (OR, 0.353; p=0.0569).

Conclusions:

• While not statistically significant, rotigotine use may be associated with a reduced incidence of PHS.
• Maintaining consistent medication adherence is crucial for PHS prevention.
• Rotigotine presents a potential therapeutic option for managing PHS risk in PD patients.